TrialSignal transduction and targeted therapy2024

Neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus: NEOTAX, a phase 2 study.

Liangyou Gu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.